Carina Schmidt has been appointed as the Chairperson of Lipigon Pharmaceuticals, she succeeds Gisela Sitbon. Carina has, as CEO of Athera, hands on experience in bringing a pre-clinical asset into late stage clinical development in the cardiometabolic field. She will therefore provide invaluable guidance as support for coming preclinical and clinical stages. With her experience she will help guide Lipigon into clinical development.

"We are very happy to have such an experienced professional on the board. Carina will bring with her 35 years of life science experience. She has achieved great things with Athera Biotechnologies so today we are very pleased welcoming her to the Lipigon team", said CEO Stefan K Nilsson.

For further information, please contact:

Stefan K. Nilsson, CEO, Lipigon Pharmaceuticals


Tel: +46 70 578 17 68

About Lipigon Pharmaceuticals

Lipigon was founded by leading scientists in the field lipid biology. Lipigon is currently focusing on the discovery and development of first-in-class treatments for lipid related diseases in the orphan space. For more information please visit:


19 maj, 2022, Pressmeddelande

Kommuniké från extrastämma i Lipigon Pharmaceuticals AB den 19 maj 2022

Idag, den 19 maj 2022, hölls extra bolagsstämma i Lipigon Pharmaceuticals AB. Extra bolagsstämman be...

19 maj, 2022, Pressmeddelande

Kommuniké från årsstämma 2022 i Lipigon Pharmaceuticals AB den 19 maj 2022

I dag, den 19 maj 2022, hölls årsstämma i Lipigon Pharmaceuticals AB. Nedan följer en sammanfattning...

18 maj, 2022, Pressmeddelande

Lipigon presenterar på Europas ledande forskarmöte om åderförfettning

Lipigons vd Stefan K. Nilsson ska hålla två presentationer om Lipisense under den prestigefyllda "La...